Mental Health Clinics in Eau Claire, WI Accepting Medicare
63 Mental Health Clinics found. Showing 61 - 63
 Thrive Psychiatry Inc. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 312 S Barstow St, Eau Claire, WI 54701 Phone: 816-810-9841 |
Authentic Mental Health, Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 505 S Dewey St, Eau Claire, WI 54701 Phone: 715-828-3721 |
Marriage & Family Health Services Ltd Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2925 Mondovi Rd, Eau Claire, WI 54701 Phone: 715-832-0238 Fax: 715-832-0771 |
News Archive
Chemspec board authorizes share repurchase program
Chemspec International Limited, a leading China-based contract manufacturer of highly-engineered specialty chemicals, today announced that its board of directors has authorized a share repurchase program that would allow the Company to repurchase up to US$10 million of its American Depositary Shares ("ADSs") on the open market between September 22, 2010 and September 21, 2011.
Working memory defects could explain why some children have problems learning
New research from Britain is suggesting that defects in their working memory may explain the problems some children have with learning.
Thrombogenics issues business update and half year results
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.
Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis
Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
Peplin completes four-week enrolment phase for REGION-Ib trial
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
› Verified 7 days ago